U.S. markets close in 1 hour 57 minutes

BioDelivery Sciences International, Inc. (BDSI)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.59-0.00 (-0.09%)
As of 03:00PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close5.59
Bid0.00 x 28000
Ask0.00 x 36200
Day's Range5.59 - 5.60
52 Week Range2.50 - 5.62
Avg. Volume3,352,473
Market Cap577.05M
Beta (5Y Monthly)N/A
PE Ratio (TTM)6.82
Earnings DateMar 07, 2023 - Mar 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.38
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
10% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for BDSI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • BioDelivery Sciences Internatio
    Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We CoverIn this edition, Bank of Queensland should generate some interest; China telecom sends out signals of recovery; Want to know who dominates online searching? Google it; and Brookfield Renewable, Kohl's, and Daiichi.
    Fair Value
    Economic Moat
View more
  • GlobeNewswire

    Genenta Announces Nomination of Mark A. Sirgo as Chair

    35 years industry experience including as CEO and founder of public company Stephen Squinto steps down as Chair for new role MILAN, Italy and NEW YORK, April 27, 2022 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for cancer, announced the nomination of Mark A. Sirgo, PharmD, an executive leader with over 35 years of pharmaceutical industry experience, as its new Chair

  • GlobeNewswire

    Collegium Completes the Acquisition of BDSI

    STOUGHTON, Mass., March 22, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) (“Collegium”) today announced that it has completed the acquisition of BioDelivery Sciences International Inc. (Nasdaq: BDSI) (“BDSI”). “This acquisition is a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions,” said Joe Ciaffoni, President and Chief Executive Officer of

  • Zacks

    Merck (MRK) Keytruda Gets Another FDA Nod in Endometrial Cancer

    Merck's (MRK) Keytruda gets approval for advanced endometrial carcinoma therapy in certain patients who are not suited for curative surgery or radiation.